Billiontoone (NASDAQ:BLLN) Price Target Lowered to $140.00 at BTIG Research

Billiontoone (NASDAQ:BLLN) had its price objective decreased by BTIG Research from $160.00 to $140.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. BTIG Research’s price objective would suggest a potential upside of 73.20% from the company’s current price.

Several other equities analysts have also recently issued reports on BLLN. JPMorgan Chase & Co. lowered their price objective on Billiontoone from $150.00 to $145.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 10th. Wall Street Zen upgraded Billiontoone to a “hold” rating in a research note on Saturday, November 15th. Wells Fargo & Company started coverage on Billiontoone in a research report on Monday, December 1st. They set an “equal weight” rating and a $110.00 price objective on the stock. Stifel Nicolaus initiated coverage on Billiontoone in a research report on Monday, December 1st. They issued a “buy” rating and a $145.00 target price for the company. Finally, Piper Sandler restated an “overweight” rating on shares of Billiontoone in a research note on Wednesday, December 10th. Six investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Billiontoone currently has an average rating of “Moderate Buy” and a consensus price target of $132.43.

Billiontoone Stock Performance

NASDAQ:BLLN opened at $80.83 on Thursday. The company has a market cap of $3.70 billion and a price-to-earnings ratio of 808.30. Billiontoone has a fifty-two week low of $66.00 and a fifty-two week high of $138.70. The company’s 50-day moving average price is $86.15.

Billiontoone (NASDAQ:BLLN) last issued its earnings results on Wednesday, March 4th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.07. The firm had revenue of $96.05 million during the quarter, compared to the consensus estimate of $85.85 million. The company’s revenue was up 113.0% compared to the same quarter last year.

Hedge Funds Weigh In On Billiontoone

Several institutional investors have recently made changes to their positions in BLLN. Adams Street Partners LLC purchased a new position in shares of Billiontoone in the fourth quarter worth approximately $140,063,000. Baillie Gifford & Co. bought a new position in Billiontoone in the fourth quarter worth approximately $103,786,000. Price T Rowe Associates Inc. MD purchased a new position in shares of Billiontoone during the 4th quarter worth $39,717,000. JPMorgan Chase & Co. bought a new stake in shares of Billiontoone during the 4th quarter valued at $32,078,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in shares of Billiontoone in the 4th quarter worth $18,631,000.

Trending Headlines about Billiontoone

Here are the key news stories impacting Billiontoone this week:

• Positive Sentiment: BLLN reported better-than-expected Q4 results: $0.11 EPS vs. $0.04 consensus and revenue up ~113% year-over-year — a clear beat that supports growth expectations. BillionToOne Q4 results and call
• Positive Sentiment: The company raised FY2026 revenue guidance to $430M–$445M versus a prior consensus near $356M — a material upward revision that implies meaningful topline acceleration and is a primary positive catalyst. GlobeNewswire press release
• Positive Sentiment: Management commentary and the earnings call highlighted record revenue growth and strategic initiatives to scale diagnostic adoption — supportive for medium-term execution. Earnings call highlights (Yahoo)
• Neutral Sentiment: Analysts (Zacks and others) are parsing key metrics versus estimates to assess sustainability of the growth beat; deeper metric analysis will inform revisions to models and investor expectations. Zacks earnings metrics analysis
• Neutral Sentiment: Company released the official press release and slide deck for the quarter — useful for investors building financial models but not a new catalyst by itself. Press release / slide deck
• Neutral Sentiment: Reported short-interest data in early March appears inconsistent (values show zero/NaN), so it’s not currently a reliable explanation for price moves; any future verified rise in short interest would be a potential headwind.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.